Germany covid-19 vaccine DNA medicines Germany

Inovio Pharmaceuticals boosts Covid-19 vaccine manufacturing

Reading now: 488
www.pharmaceutical-technology.com

Inovio Pharmaceuticals has signed an agreement with German contract manufacturer Richter-Helm BioLogics for large-scale production of Covid-19 DNA vaccine candidate, INO-4800.

The deal, partially funded by a $1.3m initial grant from the Coalition for Epidemic Preparedness Innovations (CEPI), includes a total of $17.2m support for INO-4800 development.

Richter-Helm BioLogics has been manufacturing Inovio’s other DNA drug candidate VGX-3100 has been in manufacture since 2014, which is currently in Phase III clinical trials to treat precancerous cervical dysplasia caused by high-risk human papillomavirus (HPV).

Inovio commercial-scale plasmid manufacturing at Richter-Helm BioLogics for its DNA medicines platform. The aim is to manufacture

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA